# Janssen Sciences Ireland UC clinical trials: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with Janssen Sciences Ireland UC as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen Sciences Ireland UC: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-sciences-ireland-uc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 5, 2026 | NCT07746765 | A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting | Janssen Sciences Ireland UC | Observational | Not yet recruiting | Crohn Disease, Colitis, Ulcerative | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746765) |
| January 9, 2020 | NCT04221412 | Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and... | Janssen Sciences Ireland UC | Not applicable | No longer available | Respiratory Syncytial Virus | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04221412) |
| December 23, 2019 | NCT04208399 | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 | Janssen Sciences Ireland UC | Phase 1 | Completed | Hepatic Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04208399) |
| December 23, 2019 | NCT04208386 | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989 | Janssen Sciences Ireland UC | Phase 1 | Completed | Hepatic Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04208386) |
| October 17, 2019 | NCT04129554 | A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed... | Janssen Sciences Ireland UC | Phase 2 | Completed | Hepatitis B, Chronic | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04129554) |
| August 14, 2019 | NCT04056611 | Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With... | Janssen Sciences Ireland UC | Phase 2 | Terminated | Respiratory Syncytial Virus Infections | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04056611) |
| July 1, 2019 | NCT04002752 | A Study of JNJ-73763989 in Healthy Japanese Adult Participants | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04002752) |
| June 11, 2019 | NCT03982186 | A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus... | Janssen Sciences Ireland UC | Phase 2 | Completed | Hepatitis B, Chronic | 471 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03982186) |
| May 10, 2019 | NCT03945539 | A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03945539) |
| February 20, 2019 | NCT03847376 | Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human... | Janssen Sciences Ireland UC | Not applicable | Approved for marketing | HIV | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03847376) |
| March 13, 2018 | NCT03463369 | A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by... | Janssen Sciences Ireland UC | Phase 1 | Completed | Hepatitis B, Chronic | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03463369) |
| December 5, 2017 | NCT03361956 | An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection | Janssen Sciences Ireland UC | Phase 2 | Completed | Hepatitis B | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03361956) |
| April 12, 2017 | NCT03111511 | A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of... | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03111511) |
| January 25, 2016 | NCT02662712 | A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One... | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy, Hepatitis, Chronic | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02662712) |
| November 2, 2015 | NCT02593851 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants... | Janssen Sciences Ireland UC | Phase 1 | Terminated | Respiratory Syncytial Virus Infections, Virus Diseases | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02593851) |
| October 19, 2015 | NCT02578550 | A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02578550) |
| September 28, 2015 | NCT02561936 | Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02561936) |
| July 13, 2015 | NCT02494986 | A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine... | Janssen Sciences Ireland UC | Phase 2 | Completed | Human Immunodeficiency Virus Type 1 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02494986) |
| June 18, 2015 | NCT02475135 | Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02475135) |
| April 30, 2015 | NCT02431247 | A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination... | Janssen Sciences Ireland UC | Phase 3 | Completed | Immunodeficiency Virus Type 1, Human | 725 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02431247) |
| April 27, 2015 | NCT02426632 | Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02426632) |
| April 20, 2015 | NCT02421211 | A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir... | Janssen Sciences Ireland UC | Phase 2 | Completed | Hepatitis C, Chronic | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02421211) |
| March 25, 2015 | NCT02398591 | A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02398591) |
| March 13, 2015 | NCT02387606 | Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against... | Janssen Sciences Ireland UC | Phase 2 | Completed | Respiratory Syncytial Virus Infections | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02387606) |
| March 11, 2015 | NCT02385071 | A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With... | Janssen Sciences Ireland UC | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02385071) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 2 | 9 |
| Phase 3 | 3 |
| Not applicable | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Terminated | 2 |
| Not yet recruiting | 1 |
| No longer available | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Acquired Immunodeficiency Syndrome | 5 |
| Respiratory Syncytial Virus Infections | 3 |
| Hepatitis B, Chronic | 3 |
| HIV Infections | 2 |
| Hepatitis, Chronic | 1 |
| Hepatitis C, Chronic | 1 |
| Virus Diseases | 1 |
| Crohn Disease | 1 |
| Colitis, Ulcerative | 1 |
| Hepatitis B | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drywall contractors in the United States](https://specstream.ai/data/businesses/drywall-contractors/united-states)
- [Patent law firms in the United States](https://specstream.ai/data/businesses/patent-law-firms/united-states)
- [Avionics shops in the United States](https://specstream.ai/data/businesses/avionics-shops/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
- [Chimney sweeps in the United States](https://specstream.ai/data/businesses/chimney-sweeps/united-states)
